Systemic outcomes of adalimumab therapy, expressed per-person ‘at risk’
| Outcome | 6 weeks | 6 months | 12 months | 18 months | 24 months | 30 months | |||||||
| Per-person | Characteristic required to be ‘at risk’ | Events/at risk | Rate per 100 (95% CI) | Events/at risk | Rate per 100 (95% CI) | Events/at risk | Rate per 100 (95% CI) | Events/at risk | Rate per 100 (95% CI) | Events/at risk | Rate per 100 (95% CI) | Events/at risk | Rate per 100 (95% CI) |
| Active patients | |||||||||||||
| Reduction of prednisolone to≤10 mg/day | >10 mg/day at baseline | 5/8 | 62.5 (30.4 to 86.5) | 8/8 | 100 (62.8 to 100*) | 6/7 | 85.7 (46.7 to 99.5) | 2/5 | 40.0 (11.6 to 77.1) | 4/4 | 100 (45.4 to 100*) | 3/3 | 100 (38.3 to 100*) |
| Reduction in number of systemic steroid-sparing agents to ≤ 1 | >1 systemic steroid-sparing agent at baseline | 1/3 | 33.3 (5.6 to 79.8) | 2/3 | 66.7 (20.2 to 94.4) | 1/1 | 100 (16.7 to 100*) | 0/0 | n/a | 0/0 | n/a | 0/0 | n/a |
| Inactive patients | |||||||||||||
| Reduction of prednisolone to≤10 mg/day | >10 mg/day at baseline | 4/4 | 100 (45.4 to 100*) | 4/4 | 100 (45.4 to 100*) | 3/3 | 100 (38.3 to 100*) | 2/2 | 100 (29.0 to 100*) | 2/2 | 100 (29.0 to 100*) | 1/1 | 100 (16.7 to 100*) |
| Reduction in number of systemic steroid-sparing agents to ≤1 | >1 systemic steroid-sparing agent at baseline | 1/2 | 50.0 (9.5 to 90.5) | 1/2 | 50.0 (9.5 to 90.5) | 2/2 | 100 (29.0 to 100*) | 1/1 | 100 (16.7 to 100*) | 1/1 | 100 (16.7 to 100*) | 1/1 | 100 (16.7 to 100*) |
*Indicates the Agresti-Coull CI was clipped at the upper endpoint.